- Home
- SMLR vs GLSI Comparison
SMLR vs GLSI Comparison
Compare SMLR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMLR
- GLSI
- Stock Information
- Founded
- SMLR 2007
- GLSI 2006
- Country
- SMLR United States
- GLSI United States
- Employees
- SMLR N/A
- GLSI N/A
- Industry
- SMLR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- SMLR Health Care
- GLSI Health Care
- Exchange
- SMLR Nasdaq
- GLSI Nasdaq
- Market Cap
- SMLR 289.5M
- GLSI 197.1M
- IPO Year
- SMLR 2014
- GLSI 2020
- Fundamental
- Price
- SMLR $54.26
- GLSI $13.76
- Analyst Decision
- SMLR
- GLSI Strong Buy
- Analyst Count
- SMLR 0
- GLSI 1
- Target Price
- SMLR N/A
- GLSI $38.00
- AVG Volume (30 Days)
- SMLR 317.4K
- GLSI 23.4K
- Earning Date
- SMLR 11-04-2024
- GLSI 11-19-2024
- Dividend Yield
- SMLR N/A
- GLSI N/A
- EPS Growth
- SMLR N/A
- GLSI N/A
- EPS
- SMLR 2.04
- GLSI N/A
- Revenue
- SMLR $58,938,000.00
- GLSI N/A
- Revenue This Year
- SMLR N/A
- GLSI N/A
- Revenue Next Year
- SMLR N/A
- GLSI N/A
- P/E Ratio
- SMLR $19.55
- GLSI N/A
- Revenue Growth
- SMLR N/A
- GLSI N/A
- 52 Week Low
- SMLR $20.88
- GLSI $8.00
- 52 Week High
- SMLR $54.43
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- SMLR 83.35
- GLSI 50.06
- Support Level
- SMLR $36.23
- GLSI $13.67
- Resistance Level
- SMLR $44.52
- GLSI $14.67
- Average True Range (ATR)
- SMLR 3.98
- GLSI 0.75
- MACD
- SMLR 2.33
- GLSI 0.06
- Stochastic Oscillator
- SMLR 91.79
- GLSI 68.97
About SMLR Semler Scientific Inc.
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.